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Abstract: Vascular calcification (VC) is common in dialysis and non-dialysis chronic kidney disease
(CKD) patients, even in the early stage of the disease. For this reason, it can be considered a CKD
hallmark. VC contributes to cardiovascular disease (CVD) and increased mortality among CKD
patients, although it has not been proven. There are more than one type of VC and every form
represents a marker of systemic vascular disease and is associated with a higher prevalence of CVD
in CKD patients, as shown by several clinical studies. Major risk factors for VC in CKD include:
Increasing age, dialysis vintage, hyperphosphatemia (particularly in the setting of intermittent or
persistent hypercalcemia), and a positive net calcium and phosphate balance. Excessive oral calcium
intake, including calcium-containing phosphate binders, increases the risk for VC. Moreover, it has
been demonstrated that there is less VC progression with non-calcium-containing phosphate binders.
Unfortunately, until now, a specific therapy to prevent progression or to facilitate regression of VC
has been found, beyond careful attention to calcium and phosphate balance.
Keywords: hyperphosphatemia; chronic kidney disease; secondary hyperparathyroidism; vascular
calcification; phosphate binder
Key Contribution: Phosphate plays a central role on vascular calcification, particularly in
patients suffering from chronic kidney disease. Novel insights into the pathogenesis of high
phosphate-induced vascular calcification might help to find specific therapies.
1. Introduction
Cardiovascular disease (CVD) is the most common cause of death in patients with chronic kidney
disease (CKD) [1]. The high cardiovascular risk may be due in part to excess vascular calcification
(VC), which is observed even in very young dialysis patients, who lack the typical cardiovascular
risk factors of hypertension, dyslipidemia, and smoking [2–4]. Furthermore, studies suggest that
oral calcium intake, particularly by calcium-containing phosphate binders, worsens VC among CKD
patients. However, there is no specific therapy to prevent progression, or to facilitate regression of VC,
beyond careful attention to calcium and phosphate balance.
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There are two types of VC in CKD patients, with different pathogenesis [5,6]: Medial and intimal
calcification. Medial calcification occurs as a result of both a phenotype switch of vascular smooth muscle
cells (VSMCs) to osteoblast–like cells and local inflammation [5,7–9]. The phenotype change is initiated
by hyperphosphatemia, hypercalcemia, and, possibly, high concentrations of parathyroid hormone
(PTH) [10,11]. Hyperphosphatemia increases activity of the sodium-dependent cotransporters, PiT-1 and
PiT-2 [12], which upregulates genes associated with matrix mineralization [5,7,12,13]. Hypercalcemia
and hyperphosphatemia both increase the release of matrix vesicles, resulting in the deposition of
hydroxyapatite in the extracellular matrix [14,15]. Intimal calcification is secondary to established
atherosclerosis. The pathogenesis of atherosclerosis appears to be the same in non-CKD and in CKD
patients, even if shear stress, local inflammation, and calcification of VSMC-derived microvesicles,
are amplified in CKD patients, so accelerating the calcification process in the intima [16]. Many of the
factors that cause medial calcification (hyperphosphatemia, hypercalcemia, and hyperparathyroidism)
probably worsen intimal calcification. In addition, the arterial stiffness caused by medial calcification
likely directly contributes to shear stress, atherosclerosis, and intima calcification [17].
Fibroblast Growth Factor 23 (FGF23) is a hormone produced by bone cells (both osteoblasts and
osteocytes) in response to vitamin D and high phosphate load [18]. Elevated circulating levels of
FGF23 lead to phosphate-wasting disorders, and strongly suppresses renal 1α-hydroxylase expression,
causing a reduction of the synthesis of the vitamin D hormone 1α,25-dihydroxyvitamin D3 in kidney
proximal tubules [18]. The FGF23-related suppression of renal 1α-hydroxylase appears to be a
physiologically crucial process. Clearly, high circulating calcitriol levels caused by loss of FGF23
function are not detrimental per se, but the toxicity is rather greatly caused by hyperphosphatemia
and hypercalcemia, both induced by increased vitamin D activity.
2. Definitions and Clinical Significance of VC
Cardiovascular calcification (CVC) associates with several diseases, including end stage renal
disease (ESRD) and CVD.
Calcium phosphate deposition, especially in the form of apatite, is the hallmark of CVC and can
occur in the blood vessels, myocardium, and cardiac valves. Calcium phosphate deposits are present
in distinct layers of the blood vessel and associate with specific pathologies.
So far, no study has systematically evaluated the distribution of CVC at different sites in large
CKD populations across stages of disease.
There are four different types of VC [19]: Intimal artery calcification or medial artery calcification,
valvular calcifications, and calciphylaxis. Distinguishing medial from intimal calcification is possible
with a light microscopic examination: Intimal calcification is disclosed as irregular, discrete, plague-like
calcification, whereas medial calcification reveals tram-tract, non-stenotic diffuse calcified wall
thickness in radiological and ultrasonographic images. Evaluation of coronary artery calcification
(CAC) by computed tomography detects and quantifies vascular and valvular calcifications and
is an accepted tool for CVC risk assessment but it is not able to discriminate between intimal and
medial calcification.
Medial calcification is an active process detectable in the course of ageing, CKD, and diabetes,
and secondary to mineral bone disorders, inflammatory status, humoral factors, and phenotypic switch
of resident cells. Compared to calcification of the media layer, current evidence points to a different
sequence of events driving calcification in atherosclerotic plaque [20–22]. Calcification in the intima
appears to be a secondary to inflammation, but still dependent on VSMCs and macrophage infiltration
into the early atheromatous lesion and on the effect of humoral factors.
In ESRD patients, both intimal and medial calcification occur, but arterial medial calcification is
the most prevalent [5]. Thus, both intimal and medial calcification are probably the major contributors
to the 10- to 100-fold increase in cardiovascular mortality risk observed in ESRD patients [17].
The clinical consequences of intimal versus medial layer calcification, although often coexisting in
the same patient, may be very different [23,24]. The main consequence of intimal disease is probably
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plaque rupture and acute vessel occlusion, whereas medial calcification induces arterial stiffness with
the consequent increase in systolic blood pressure that contributes to left ventricular hypertrophy
(LVH) (Figure 1).
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Epidemiological and clinical studies have highlighted an association between serum phosphate
levels and VC, even in the normal range at every stage of the renal disease, and also in the general
population [25–28]. Due to these results, and to the findings of experimental models, phosphate is now
accepted as a major direct inducer of VC.
To better elucidate the relationship between calcium and phosphate disorders and VC, there are
two different mechanisms that are proposed: A passive mechanism, as a direct calcium–phosphate
precipitation in the vasculature, and an active process, through the induction of bone-associated genes
in VSMCs, that acquire a bone-forming (osteoblast-like) phenotype [6,9].
3. VC is An Actively Regulated Process
Growing evidence suggests that CVC is a highly regulated process, involving both inductive
and inhibitory processes [29]. Under experimental conditions in vitro, cells from the tunica media
(VSMCs, adventitial fibroblasts, and pericytes) switch to osteochondrogenic differentiation and matrix
mineralization [30,31]. These studies suggest that cell-mediated processes tightly control procalcific
and anticalcific mediators in the artery. The balance between inductors and inhibitors of calcification is
fundamental to avoid ectopic calcification and maintain normal vessel physiology, even if the precise
role of each inhibitor and inducer still needs deep investigation [32]. Under pathological conditions,
this balance is modified, and results in ectopic mineralization.
The hallmark of VC involves both intima and media. It is represented by the activation of
cells committed to an osteoblastic program. Cells with an osteogenic phenotype may originate from
vascular, wall-resident, mesenchymal stem cells, transdifferentiated mature or circulating VSMCs,
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pericytes, or circulating calcifying cells (CCCs) [33]. CCCs have been associated with coronary artery
disease and calcific aortic stenosis, in both advanced CKD and diabetes [34–36]. Although their role is
not yet fully defined, the detection and recognition of CCCs is a critical step in the understanding of
CVC pathogenesis. However, up to now, there are still limited data available concerning the factors
related to the presence of CCCs, and there is no clear proof of CCCs actively participating in vascular
medial calcification.
The current major theories to explain VC include: (1) loss of inhibition, (2) induction of
osteochondrogenesis, (3) apoptosis, (4) abnormal calcium and phosphate homeostasis, (5) circulating
nucleation complexes/paracrine factors derived from bone, and (6) matrix degradation.
Recently, Moe’s research group [37], demonstrated that VSMCs matrix vesicles can be considered
as propagator of calcification in non-calcified VSMCs. In fact, VSMCs from aorta of CKD rats are able
to secrete microvesicles that induce healthy VSMCs to calcify.
These data confirm a cell–to–cell communication in the pathogenesis of VC and account for the
evidence that patients at the beginning of dialysis showing artery calcification, have a more rapid
progression of calcification itself [38]. Matrix vesicles were endocytosed by healthy VSMCs, with an
increase of intracellular calcium concentration, and specific enzyme pathways were activated.
An important role in the calcification process development is played by the uremic serum milieu
with uremic toxins and phosphate as key regulators of VC in ESRD. It has been demonstrated that
serum from uremic patients either induces or accelerates calcium deposition in vitro due to the
presence of a complex miscellaneous of uremic factors [39–41]. Recently, it has been shown that
there is a significant positive correlation between the degree of VC in vivo and the serum calcific
potential, in high-Pi condition, in vitro through a higher potential to induce VSMCs osteoblastic
trans-differentiation, apoptosis, and necrosis [42].
4. VSMCs: A Model System to Investigate Mechanisms of VC In Vitro
VSMCs classically exhibit a contractile phenotype and reside in the media of blood vessels.
These cells highly express genes that are required for the maintenance of myofilament function and
structure. VSMCs phenotype is characterized by the ability to reversibly enter in a synthetic state
of production and proliferation of large amounts of extracellular matrix. Therefore, VSMCs can
be activated from a quiescent, differentiated state into an actively synthesizing and proliferating
phenotype. This phenotypic change associates with reduction of smooth muscle cell markers and
can be induced by several stimuli in vitro, including mechanical stress, injury, and growth factors [3].
This finding, however, is controversial as synthetic VSMCs may derive from vascular stem cells (VSCs)
found in all three layers of the vascular wall. After vascular injury, medial mature VSMCs die while
VSCs differentiate into synthetic VSMCs or other cell types contributing to vascular repair or lesion
progression [43] Whatever the cell population from which synthetic VSMCs derive, chronic, low-grade
inflammation, oxidative stress, and mineral bone disorders —hallmarks of CKD—are also strong
inducers of VSMCs dysfunction.
Once a synthetic phenotype is aquired, the VSMCs switch their morphology, proliferate, start to
migrate, and synthesize enormous amounts of extracellular matrix components leading to arterial
remodelling. For the repair of vascular damage, these functional changes are essential [44], but VSMCs
may also induce the development of several vascular diseases, including hypertension, atherosclerosis,
and CVC. Recently, the role of endothelium has been found to significantly contribute to VC through
endothelial-mesenchymal transitions [45] In particular, endothelial cells (ECs) line the vessel walls and
are in contact with blood, displaying heterogeneity in their response to exogenous stimuli. These ECs
play an important role in the homeostasis of the vascular system, and when ECs are exposed to various
environments, undergo dynamic phenotypic switching, which might result in EC dysfunction, causing
several diseases. Recent studies show the importance of endothelial to mesenchymal transition in
endothelial dysfunction during inflammation, leading to pathological states, such as renal fibrosis,
pulmonary arterial hypertension, VC, and atherosclerosis. Interestingly, cinacalcet, a calcimimetic
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agent, reduces synthesis and secretion of PTH and decreases serum levels of phosphate, suppresses
the switch of ECs into mesenchymal cells, leading to attenuation of cardiac fibrosis [46].
5. The Role of Phosphorus in the Development and Progression of VC
In the United States there are about 25 million subjects affected by CKD stages 2 to 5, and between
them, the risk of CVD is linked to a very high mortality risk. Furthermore, patients with higher
risk of mortality are those with advanced CKD. In fact, ‘chronological’ age in a 70-year-old patient
with ESRD corresponds to a ‘biological’ age of a 90-year-old subject with normal renal function [3].
Clearly, the traditional risk factors for CVD cannot fully explain the higher increased cardiovascular
risk in CKD.
In the CKD population, CVC is associated with several non-classical risk factors that may be
unique to CKD [47]. One such factor is high serum phosphorus levels, which has been linked to
CVC in several preclinical and clinical studies and is emerging as a central regulator of extra-skeletal
calcification in the CKD population [7–9].
VC is an early feature of CKD patients and its progression is linked to high phosphate load and
hyperphosphatemia. It appears to be involved in several mechanisms that promotes and triggers VC
progression, including: (1) Transition of VSMCs from a contractile to an osteochondrogenic phenotype
and VSMCs extracellular matrix mineralization; (2) induction of VSMCs apoptosis; (3) inhibition of
monocyte/macrophage differentiation into osteoclast-like cells; (4) increased fibroblast growth factor
23 (FGF23) levels; (5) reduction in Klotho expression (Figure 2).
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Figure 2. Major regulators and effects of P on vascular calcification. Ca: calcium; FGF-23: fibroblast
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Several in vitro studies have been performed using VSMCs to determine whether phosphorus
directly affects VC. The well-known associati n b twee hyperphosphatemia and VC in CKD patients,
can be elucidated in the experime tal setting, in which VSMCs are exposed to high levels of inorganic
hosphate, considering the calcification process i duced in the extracellular matrix surrounding
VSMCs [48,49]. The master g ne for bone differentiation, named Cbfa-1 or RUNX2 (core binding
factor A1), drives the entrance of phosphate int the cytosol of VSMCs, inducing bone matrix protein
pro uction in the ext ac llular matrix.
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Similar to bone calcification, extra-skeletal calcification can be obtained by molecular and cellular
mechanisms, including matrix vesicles and bio-apatite synthesis [50]. Furthermore, phosphate directly
induces phenotypic switches in VSMCs, causing them to transform from a contractile phenotype into
an osteochondrogenic phenotype [51]. In vitro studies have examined how phosphate can induce a
change in phenotype of VSMCs; for example, cultured human aortic smooth muscle cells switch to
osteoblastic cell types at different levels of extracellular phosphate, showing a dose dependent increase
in calcium deposition into the extracellular matrix. Similarly, in a study of bovine aortic VSMCs,
mineralization in culture was associated with the tremendous loss of smooth muscle-specific gene
expression in the presence of an organic phosphate donor, β-glycerol phosphate [52]. Interestingly,
protection from high-phosphate induced smooth muscle marker down-regulation in VSMCs reduces
calcification [53].
Thus, during CKD, phosphate load increases and accumulates outside bones, determining the
fact that phosphate can be considered a ‘uremic toxin’. Of course, the effects of phosphate on biological
systems are extremely important, but the adverse effects of hyperphosphatemia in CKD should be
emphasized, even in early stages of the disease. Therefore, in combination with several factors,
hyperphosphatemia can cause damage in several cells and tissues, such as bones, parathyroid glands,
and, most importantly, the heart and vessels. In fact, hyperphosphatemia strongly associates with
vascular and valvular calcification, arteriosclerosis, and an increased risk of cardiovascular death,
especially in advanced CKD patients.
6. Phosphate-Induced Apoptosis of VSMCs
Some studies support a link between VSMCs apoptosis and VC, suggesting that apoptosis is
a key regulator of VSMCs calcification [32,54,55]. Proudfoot et al. [56] reported that, in a human
in vitro VSMCs calcification model, apoptosis occurred before calcium deposition and demonstrated
that inhibiting apoptosis inhibits calcification, whereas stimulating apoptosis increases calcification.
In 2008, Shroff et al. [57] studied the effects of dialysis treatment on accelerated atherosclerosis and
arteriosclerosis, in part by triggering smooth muscle cell apoptosis. Interestingly, VSMCs in vessels of
dialysis patients showed increased apoptosis and dramatic damage. In this study, they hypothesize
that calcium accumulation in the vessel begins in response to increased levels of calcium and
phosphate. Moreover, they hypothesize that protective mechanisms, such as the maintenance of
adequate mineralization inhibitor levels and extrusion of intracellular calcium via vesicle release,
preserves normal VSMCs function.
In the dialysis milieu, uremic toxins and the continued exposure to high-Pi lead to apoptosis.
This, in turn, increases local Ca++ deposition and reduces levels of VSMC-derived mineralization
inhibitors, which potentiates osteo/chondocytic differentiation of VSMCs. Apoptotic cells form a nidus
for calcification, releasing apoptotic bodies loaded with calcium that start hydroxyapatite deposition
in the extracellular matrix and thus the calcification process [58].
However, Shanahan et al. [11] found that the molecular and cellular mechanisms of VC in the
experimental model of VSMCs does not require apoptosis for the initiation of calcification. Nonetheless,
once calcium phosphate crystals are deposited in the matrix, the calcification process is accelerated
by increased apoptosis. It has been demonstrated that VSMCs are able to be phagocytosed by both
human and synthetic atherosclerosis-derived calcium phosphate crystals, resulting in a rapid increase
in intracellular calcium concentrations and consequent inflammation and apoptosis [59].
Recently, Shanahan et al. [11] hypothesized a close interplay between apoptotic bodies formation
in VSMCS and phosphate-induced cell phenotype switch. Contractile VSMCs adapt to the hostile
conditions by undergoing lineage switch to a synthetic bone forming phenotype. These cells are able
to secrete matrix vesicles, in the attempt to avoid calcium overload. On the contrary, VSMCs that fail
to differentiate go to apoptosis, which also results in budding of matrix mineralization and vesicles.
Both pathways lead to extracellular calcium phosphate deposition, via vesicle release with enhanced
risk of apoptosis of surrounding VSMCs [11].
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7. Phosphate and Autophagy in VSMCs
Autophagy, a highly regulated and dynamic process of self-digestion, seems to play a central
role in VSMCs mineralization. The term ‘autophagic cell death’ has been widely used to indicate
a type of cell death that is accompanied by massive vacuolization of the cytoplasm [3]. However,
the relationship between cell death and autophagy remains controversial. This evidence suggests
that, although cell death can occur together with autophagy, the latter likely represents a pro-survival
mechanism activated by dying cells, trying to cope with stress [8,9].
Dai et al. [60] demonstrated that, although the inhibition of autophagy reduced
phosphate-induced VSMCs apoptosis, it caused an increment in calcium deposition in both animal
(bovine and rat VSMCs) and human aortic cells. Moreover, their results showed that the induction of
autophagy is correlated with a decrease of calcification in bovine VSMCs and rat aortic rings. Thus,
autophagy may be an endogenous protective mechanism counteracting phosphate-induced VC not
acting by the decrease of VSMCs apoptosis, but acting by the reduction of matrix vesicle release.
8. Iron, Phosphate, and VC
One of the main debated issues regarding VC is the possibility to block and eventually reverse
already established VC in order to reduce CVD morbidity and mortality in CKD patients.
Two new aluminum–calcium-free iron-based phosphate binders are now available to treat
hyperphosphatemia in CKD, namely sucroferric oxyhydroxide and iron citrate [61]. On the other hand,
iron deficiency anemia represents a serious cardiovascular complication in the CKD population.
Iron deficiency is under-diagnosed and, consequently, under-treated in CKD. The idea to have
iron-based phosphate binders beyond anemia treatment may help to counteract CVD burden in
CKD. First, the pathogenesis of iron deficiency anemia has been explored in this population, and it is
recognized that impaired intestinal absorption of dietary iron, chronic inflammation, reduced dietary
iron intake, blood loss, and increased iron requirements during therapy with erythropoietin, play a
crucial role. Clinical guidelines for anemia include: The use of iron in CKD population, with several
suggestions and only a few recommendations [62].
Recently some in vitro data on the effect of iron on VSMCs calcification has been published [63,64].
These in vitro studies attempt to clarify the direct effect of iron on the pathological pathways of VC,
independently of the iron phosphate binding effect. The same effect of calcium deposition prevention
by iron in a model of high-phosphate challenge has been demonstrated, both on human and rat VSMCs.
The two groups investigated different aspects of the VC process. It has been found that the increased
expression and ferroxidase activity of the ferritin heavy chain prevents VC by an inhibition of VSMCs
osteoblastic transformation [65]. Furthermore, the calcification inhibition by iron is also driven by the
prevention of apoptosis and the enhancement of autophagy. These data account for iron having an
impact in preventing high-Pi induced calcium deposition in vitro. However, interestingly, iron, added
when the calcification is already there, in a protocol called ‘therapeutic’ similar to ‘clinical practice’,
has the ability to completely stop the high-phosphate induced time-dependent calcium deposition [64].
This result is highly surprising, considering that after 7 or more days of high-Pi challenge the VSMCs
that receive iron are already transformed in simil-osteoblasts and actively deposit calcium-phosphate
crystals. However, in the ‘prophylactic’ approach, when VSMCs cells receive high-phosphate and
iron, their phenotype is muscular, and iron may act on the prevention of high-phosphate induced VC
mechanisms. Thus, with ‘therapeutic’ administration of iron in vitro, it is possible to completely block
calcium deposition, even if VSMCs are already transformed in simil-osteoblasts and actively deposit
calcium hydroxyapatite.
Considering that the main detrimental effect of VC is the altered stiffness of the vessel wall,
another important aspect in vascular calcification is probably played by the extracellular matrix (ECM)
characteristics modification.
A recent study by Ciceri et al. [64], showed that iron citrate is able to redirect ECM characteristics
towards muscular ECM if administered when calcification is already established. In fact, a ’therapeutic’
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addition of iron, besides blocking the osteo-chondrogenic shift of granules and inducing no additional
deposition of acidic mucins typical of cartilage and bone, was able to protect the aortic wall from the
progression of high-Pi induced fibrosis development, promoting an apparent fibril rearrangement
and block of high-Pi induced thickening of collagen fibrils. Interestingly, iron was also able to induce
an improvement in the elastic structure of the vessel wall through the protection of the aortic wall
from high-Pi induced progression of elastinolysis and to revert it. In order to understand the effect
of intravenous administration of iron in CKD patients at different stages, new research will clarify
the pathways underlying the role of iron in an in vivo model of VC. Interestingly recent evidence
shows that it may be possible to block calcium deposition and partially revert some VC aspects, at least
in vitro.
9. Phosphate and VC in the Healthy Population
Two prospective studies of large cohorts of healthy adults have demonstrated that phosphate
levels at the upper limit of the normal range, and in any case >3.9 mg/dL, are independently associated
with a greater likelihood and a more rapid progression of, coronary artery calcium.
In the first study, an association between serum phosphate levels and coronary artery calcification
was evaluated in 3015 individuals enrolled in the Coronary Artery Risk Development in Young Adults
(CARDIA).
The presence of CAC, assessed by computed tomography 15 years later, was found to be
significantly associated with serum phosphate levels [25].
In the second study, each 1-mg/dl increase in phosphorus imparted odds ratios for CAC of 1.61
(incidence) and 1.54 (prevalence), risks comparable to traditional CVD risk factors. Unfortunately,
no indexes of mineral metabolism, above all, PTH, vitamin D levels, and FGF23, were evaluated in
neither study [66].
In 1938 individuals enrolled in the cardiovascular health study, Linefsky and his group observed
an association between serum phosphate levels and cardiac valve calcification in a population-based
cohort with normal renal function. Importantly, associations were not observed between PTH, calcium,
or 25-OHD levels and calcification outcomes [26].
10. Phosphate and VC in CKD
Adeney et al. studied more than 400 multi-ethnic participants with mild to moderate CKD,
with no clinical evidence of CVD. These authors reported that each 1 mg/dL (0.32 mmol/L) increase
in phosphate level is independently and strongly associated with an higher prevalence of coronary
artery, thoracic, aortic valve, and mitral VC [27].
In a CRIC (Chronic Renal Insufficiency Cohort) study, more than 1000 CKD patients were
investigated for presence of VC. In fact, CAC progression was associated with the following disorders:
Mineral metabolism, inflammation indexes, and kidney function. The annual change in CAC score
was significant for p values above 3,9 mg/dL. Moreover, higher CAC score significantly associated
with both high serum PTH and FGF23 levels [67].
These findings were not confirmed in a further analysis of more than 500 CKD patients without
clinical signs of CVD enrolled in the MESA (Multi-Ethnic Study of Atherosclerosis) study, in which
CAC was measured at baseline and after 19 and 38 months. In this study, the presence of diabetes
has been described as a significant predictor of incidence of CAC, while the male gender has been
identified as a significant predictor of progression of CAC [68].
Many researchers are looking for serum biomarkers to identify VC patients. Very recently a
new test, named maturation time (T50) of calciprotein particles in serum, has been proposed as a
novel in vitro blood test that should provide a propensity score to extra-skeletal calcification. This T50
test is based on considering the difference in timing of the change of calcium phosphate–containing
primary CPP to hydroxyapatite–containing secondary CPP. Both forms of CPP are formed in vitro
on the addition of very high concentrations of buffered calcium and phosphate solutions to serum of
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patients [69]. The balance of either initiating or inhibiting factors into each serum sample rules the
transformation time (serum calcium phosphate precipitation time [T50]).
High serum calcification propensity (i.e., reduced serum T50), defining the overall tendency to
calcify, associates with progressive aortic stiffening, and is, therefore, a predictor of poor survival.
In a prospective cohort of almost 200 patients with early CKD stages (3 and 4), with a median of
5.3 years of follow-up, the authors described how baseline T50 independently associated with aortic
pulse wave velocity in all randomized patients, while in about 50% of CKD patients, progressive aortic
stiffening was associated to T50 after 30 months of follow-up. Indeed, the lowest T50 was principally
dependent on serum phosphate levels and serum Fetuin-A levels [70].
11. Phosphate and VC in ESRD
VC is significantly associated with the cardiovascular prognosis of ESRD patients [71,72]. In a
study conducted on 237 patients on hemodialysis and peritoneal dialysis, hypercalcemia and secondary
hyperparathyroidism, unlike hyperphosphatemia, associated with an increased risk of progression
of aortic calcification [73]. Another study on aortic calcification, included 184 peritoneal dialysis
/haemodialysis patients and found that dialysis vintage, the baseline calcification score, and the
presence of diabetes associated with progression of CVC, without derangement of biomarkers of
mineral metabolism [74].
On the other hand, Shang et al., in 207 adult patients on peritoneal dialysis, found that high
serum phosphate levels and aging are independent risk factors for CAC progression and that high
body mass index shows a trend of increased prevalence in peritoneal dialysis patients. Moreover,
serum phosphate levels are positively associated with nutritional biomarkers and peritoneal dialysis
adequacy, indicating that a high daily phosphate intake and peritoneal dialysis inadequacy may
accelerate CAC progression [28].
FGF23 is a major regulator of phosphorus metabolism in health and disease, and its synthesis
is stimulated by the expansion of the organic phosphate pool. Serum FGF23 levels increase
very early during CKD, considering the late development of hyperphosphatemia. Thus, in CKD,
both high FGF23 and PTH levels are considered very sensitive and the earliest markers of deregulated
phosphate homoeostasis.
It has been described by Nasrallah et al. that serum FGF23 was independently associated with
calcification of the aorta in patients on dialysis not affected by diabetes. These authors studied
how serum phosphate levels did not correlate with CVC, but highlighted an interesting interaction
between serum FGF23 levels and aortic calcification index, independent of serum phosphate levels [75].
In agreement with this report, Ozkok et al., in 74 haemodialysis patients, found that the association
between serum FGF23 levels and progression of CAC score was independent of serum phosphorus
levels [76]. In logistic regression analysis, the higher coronary artery calcification progression
was significantly associated with serum FGF23, phosphorus levels, and baseline coronary artery
calcification score.
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